. Author manuscript; available in PMC: 2022 Jun 22.

Published in final edited form as: Eur Respir J. 2022 Apr 21;59(4):2100905. doi: 10.1183/13993003.00905-2021

Table 4. Association between high concentration of IL-6 at baseline and unfavorable tuberculosis treatment outcomes in the pooled validation analysis.

Treatment outcomes	Odds ratios for unfavorable treatment outcomes
	Unadjusted (95%CI)	p-value	Adjusted (95%CI)	p-value
Composite	3.32 (2.02-5.46)	<0.001	3.45 (2.03-5.89)	<0.001
Failure	2.16 (1.08-4.33)	0.02	2.22 (1.04-4.75)	0.03
Recurrence	5.36 (2.48-11.57)	<0.001	5.92 (2.52-13.90)	<0.001
Death	4.62 (1.95-10.95)	<0.001	5.53 (2.08-14.68)	<0.001

Regression analyses are adjusted for age, sex, BMI, cavitation on CXR, smear grade, HIV and diabetes.